| 翻訳と辞書 |
| Otelixizumab ： ウィキペディア英語版 |
Otelixizumab
Otelixizumab, also known as TRX4, is a monoclonal antibody,〔Bolt, S., Routledge, E., Lloyd, I., Chatenoud, L., Pope, H., Gorman, S., Clark, M. & Waldmann, H. (1993). The generation of humanized, non-mitogenic CD3 monoclonal antibody which retains in-vitro immunosuppressive properties. Europ. J. Immunol. 23, 403-411.〕 which is being developed for the treatment of type 1 diabetes and other autoimmune diseases. The antibody is being developed by Tolerx, Inc. in collaboration with GlaxoSmithKline and is being manufactured by Abbott Laboratories.〔(Windhover Information “GSK buys rights to Tolerx's diabetes antibody otelixizumab” )〕
==Mechanism of action==
Otelixizumab is one of several investigational monoclonal antibodies that target CD3, a T lymphocyte receptor involved in normal cell signaling. More specifically, otelixizumab targets the epsilon chain of CD3. Data suggest that the drug works by blocking the function of effector T cells, which mistakenly attack and destroy insulin-producing beta cells while stimulating regulatory T cells, which are understood to protect against effector T cell damage, thus preserving the beta cells' normal ability to make insulin.
Proof of concept was established in a randomized, placebo-controlled Phase 2 study. These data demonstrated otelixizumab’s ability to preserve beta cell function, as measured by C-peptide, in patients up to 18 months after dosing, as well as reduce the need for delivered insulin to maintain glucose control.
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「Otelixizumab」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|